The Kelly Fund for Lupus, Inc.

02/16/2026

💫 Join the Lupus Research Alliance Team Life Without Lupus for this year's Copenhagen Marathon on May 10! 🇩🇰

42.195 km through the heart of Copenhagen. Four runners share the course, enjoying a scenic route full of history and unforgettable views.

Every step helps bring us closer to a world free of lupus.

👉 Learn more & apply now: lupusresearch.org/marathons

12/09/2025

“This is a time like no other in lupus clinical research.”

Hundreds of lupus therapies are in development — many reaching Phase 3 — signaling historic progress in treatment innovation. This surge of innovation is translating into potential treatments that are targeted, safer, and showing potential effectiveness for people living with lupus — offering more choices and options for treating the disease.

Read what Stacie Bell, Chief Clinical Research Officer at clinical affiliate , and Richard Furie, Chief of the Division of Rheumatology at Northwell, say about this moment of unprecedented progress and innovation.

https://bit.ly/47zTzwH

11/11/2025

https://lupusnewstoday.com/columns/chronic-illness-checking-in-means-asking-how-ya-really-doin/

When you live with a chronic disease like lupus, it's often hard to answer "How ya doin'?" the first time, writes columnist Candace Semien.

10/20/2025

📢 Breaking news!

The U.S. Food and Drug Administration has approved Gazyva® (obinutuzumab) from Genentech to treat adults with active lupus nephritis in combination with standard of care.

This marks a major step forward for the entire lupus community, as it is the only anti-CD20 monoclonal antibody targeting an underlying cause of lupus nephritis, aiming to prevent or delay progression to end-stage kidney disease often resulting in dialysis or transplantation.

Learn more here: https://bit.ly/48FLdok

10/08/2025

CAR T-cell therapy is showing early promise as a game-changing treatment for people living with lupus.

To explore this potential, The Lupus Accelerating Breakthroughs Consortium (Lupus ABC) convened experts, regulators, and people living with lupus to tackle key questions – including safety, trial design, long-term monitoring, and more.

The result? A new paper published in RMD Open with important calls to action for making this cutting-edge therapy a reality for lupus care.

Read more: https://rmdopen.bmj.com/content/11/4/e005866

09/10/2025

is a common symptom for many individuals living with and can be challenging for many. Explore 6 possible causes of pelvic pain in lupus and strategies that may help to alleviate it here - link in the comments.

09/03/2025

https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04434-3

Lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), involves complex immune dysregulation that leads to chronic renal inflammation and progressive tissue damage. Despite decades of use of standard immunosuppressive therapy, treatment responses remain variable, and man...

08/17/2025

08/15/2025

This is wonderful news‼️💜

In lupus nephritis, attainment of complete renal response (CRR)/partial renal response (PRR) and lupus low disease activity state (LLDAS) is associated with best relapse-free survival, with independent associations seen with lupus nephritis relapse risk reduction, according to a study published onli...

08/07/2025

https://www.lupusresearch.org/lupus-research-alliance-announces-2025-empowering-lupus-research-award-recipients-to-support-breakthroughs/

Today, the Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, announced the recipients of the 2025 Empowering Lupus

07/21/2025

🙌🏾🙌🏾 https://www.nature.com/articles/s41573-025-01242-0

Hearing about advances in research is always awesome!

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical manifestations. This Review discusses advances in understanding its immunopathogenesis, the evolution of targeted therapeutic strategies, and emerging approaches to restore immune tolerance. Challenges and oppor...